Haemonetics Corporation $HAE Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 11.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,060,790 shares of the medical instruments supplier’s stock after buying an additional 111,307 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Haemonetics were worth $51,777,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HAE. Fort Washington Investment Advisors Inc. OH grew its stake in Haemonetics by 36.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock valued at $34,426,000 after acquiring an additional 187,630 shares in the last quarter. CWM LLC raised its holdings in shares of Haemonetics by 159.1% during the third quarter. CWM LLC now owns 4,733 shares of the medical instruments supplier’s stock worth $231,000 after acquiring an additional 2,906 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Haemonetics during the third quarter valued at $309,000. Inspire Investing LLC raised its position in Haemonetics by 78.4% during the third quarter. Inspire Investing LLC now owns 9,325 shares of the medical instruments supplier’s stock valued at $455,000 after acquiring an additional 4,098 shares in the last quarter. Finally, Hunter Perkins Capital Management LLC increased its holdings in shares of Haemonetics by 150.2% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 17,764 shares of the medical instruments supplier’s stock valued at $866,000 after acquiring an additional 10,664 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HAE shares. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday. Mizuho increased their target price on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Barrington Research raised their price target on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Robert W. Baird upped their price objective on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and an average price target of $84.10.

Haemonetics Trading Down 1.0%

NYSE:HAE opened at $80.14 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The business’s 50-day simple moving average is $73.82 and its 200-day simple moving average is $65.47. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The stock has a market capitalization of $3.75 billion, a PE ratio of 23.43, a price-to-earnings-growth ratio of 1.51 and a beta of 0.29.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same period in the prior year, the business earned $1.12 EPS. Haemonetics’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.